The Impact of Sequestration
Richard L. Schilsky, MD, from the University of Chicago Comprehensive Cancer Center, discusses the impact that sequestration had on the FDA.
Richard L. Schilsky, MD, Chief of Hematology/Oncology in the Department of Medicine and Deputy Director of the University of Chicago Comprehensive Cancer Center, discusses the impact that sequestration had on the FDA.
In addition to drug shortages, sequestration has recently begun to impact the FDA and other government industries in other ways. The FDA has encountered problems with staffing and sending representatives to scientific meetings.
Clinical Pearls
Schilsky says that an FDA official informed him that the administration used to send 30-40 officials to the American Society of Clinical Oncology Meeting, but only sent three in 2013. This can have a negative impact as the physicians responsible for determining what drugs go to the market cannot even attend meetings to hear data about various drugs.
- In addition to drug shortages, sequestration has recently begun to impact the FDA and other government industries in other ways
- The FDA has encountered problems with sending representatives to scientific meetings, including the ASCO Annual Meeting
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
